{"entity":{"id":"nuvox-therapeutics","kind":"company","name":"NuvOx Therapeutics","aka":["NuvOx Therapeutics, Inc.","NuvOx LLC"],"tldr":"NuvOx Therapeutics is an Arizona company developing NanO2, an infusion that carries extra oxygen into tissues. In cancer it is being tested to make radiotherapy work better against glioblastoma, a brain tumour that is often short of oxygen.","summary":"NuvOx Therapeutics, Inc., of Tucson, Arizona, develops oxygen therapeutics for conditions where hypoxia matters. Its product candidate NanO2 is an intravenous emulsion of dodecafluoropentane whose nano-sized droplets turn to gas at body temperature and deliver oxygen to tissue. In oncology it is developed as a radiotherapy sensitiser, because hypoxic tumours respond less well to radiation. The company states that NanO2 has completed phase 1/2a trials in acute ischaemic stroke and in glioblastoma, that the FDA has allowed phase 2b trials in both, and that it received orphan drug designation for glioblastoma in 2015. The phase 2 RESTORE trial (NCT03862430) tests NanO2 with radiotherapy and temozolomide in newly diagnosed glioblastoma.","asOf":"2026-11-04","links":[{"label":"SEC: NuvOx Therapeutics Form S-1/A, October 2026","url":"https://www.sec.gov/Archives/edgar/data/1966126/000121390026113463/ea0225257-14.htm"},{"label":"Official website","url":"https://www.nuvoxtherapeutics.com/"}],"tags":[],"related":[],"cancers":[],"sections":["radiation"],"technologies":["radiosensitisers","tumour-hypoxia-modification"],"targets":[],"drugs":["nano2"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on 4 November 2026 in the S-1/A filed with the SEC on 29 October 2026. RESTORE is registered on ClinicalTrials.gov by NuvOx LLC."],"hq":"Tucson, AZ","country":"US","companyType":"biotech","website":"https://www.nuvoxtherapeutics.com/","ticker":"NUOX","stage":"public","investors":[],"funding":[]},"route":"/companies/nuvox-therapeutics/","neighbours":{"section":[{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"}],"technology":[{"id":"radiosensitisers","kind":"technology","name":"Radiosensitisers","route":"/technologies/radiosensitisers/"},{"id":"tumour-hypoxia-modification","kind":"technology","name":"Tumour hypoxia: imaging and modification","route":"/technologies/tumour-hypoxia-modification/"}],"drug":[{"id":"nano2","kind":"drug","name":"NanO2","route":"/drugs/nano2/"}]}}